লনজা বলেছে যে, ক্যাপসুল এবং হেলথ ইনগ্রেডিয়েন্টs ইউনিট বিক্রি পরপর কন্ট্রাক্ট ড্রগ ম্যানufacturing বisneসে ফোকাস কমিয়ে দিয়েছে।公司预计, matured projects will drive higher profitability over the medium term. By streamlining operations and exiting non-core activities, Lonza aims to strengthen its position in the contract development and manufacturing organization (CDMO) sector. The strategic shift allows the Swiss-based firm to concentrate resources on high-growth areas within biologics and small molecule production.
Lonza’s updated guidance underscores confidence in its core capabilities amid evolving market demands. The move aligns with broader industry trends of specialization and efficiency in pharmaceutical outsourcing।.
উৎস: Wall Street Journal US Business · সারাংশ: HeadlinesBriefing